Notably, based on the evidence of IMpower 133 trial, CASPIAN trial, and CREST trial,4, 5, 6 it becomes a hot topic whether TRT should be considered to conduct in patients with small cell lung cancer (SCLC) who respond well to prior PD‐(L)1 inhibitor treatment for consolidation therapy. The gene discussed is CD274; the disease is small cell lung carcinoma.